Skip to main content
Top
Published in: Nutrition & Metabolism 1/2013

Open Access 01-12-2013 | Research

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

Authors: Bertrand Cariou, Cédric Langhi, Maëlle Le Bras, Murielle Bortolotti, Kim-Anne Lê, Fanny Theytaz, Cédric Le May, Béatrice Guyomarc’h-Delasalle, Yassine Zaïr, Roland Kreis, Chris Boesch, Michel Krempf, Luc Tappy, Philippe Costet

Published in: Nutrition & Metabolism | Issue 1/2013

Login to get access

Abstract

Background

PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its expression is driven by sterol response element binding protein 2 (SREBP2) and follows a diurnal rhythm synchronous with cholesterol synthesis. Plasma PCSK9 is associated to LDL-C and to a lesser extent plasma triglycerides and insulin resistance. We aimed to verify the effect on plasma PCSK9 concentrations of dietary interventions that affect these parameters.

Methods

We performed nutritional interventions in young healthy male volunteers and offspring of type 2 diabetic (OffT2D) patients that are more prone to develop insulin resistance, including: i) acute post-prandial hyperlipidemic challenge (n=10), ii) 4 days of high-fat (HF) or high-fat/high-protein (HFHP) (n=10), iii) 7 (HFruc1, n=16) or 6 (HFruc2, n=9) days of hypercaloric high-fructose diets. An acute oral fat load was also performed in two patients bearing the R104C-V114A loss-of-function (LOF) PCSK9 mutation. Plasma PCSK9 concentrations were measured by ELISA. For the HFruc1 study, intrahepatocellular (IHCL) and intramyocellular lipids were measured by 1H magnetic resonance spectroscopy. Hepatic and whole-body insulin sensitivity was assessed with a two-step hyperinsulinemic-euglycemic clamp (0.3 and 1.0 mU.kg-1.min-1).

Findings

HF and HFHP short-term diets, as well as an acute hyperlipidemic oral load, did not significantly change PCSK9 concentrations. In addition, post-prandial plasma triglyceride excursion was not altered in two carriers of PCSK9 LOF mutation compared with non carriers. In contrast, hypercaloric 7-day HFruc1 diet increased plasma PCSK9 concentrations by 28% (p=0.05) in healthy volunteers and by 34% (p=0.001) in OffT2D patients. In another independent study, 6-day HFruc2 diet increased plasma PCSK9 levels by 93% (p<0.0001) in young healthy male volunteers. Spearman’s correlations revealed that plasma PCSK9 concentrations upon 7-day HFruc1 diet were positively associated with plasma triglycerides (r=0.54, p=0.01) and IHCL (r=0.56, p=0.001), and inversely correlated with hepatic (r=0.54, p=0.014) and whole-body (r=−0.59, p=0.0065) insulin sensitivity.

Conclusions

Plasma PCSK9 concentrations vary minimally in response to a short term high-fat diet and they are not accompanied with changes in cholesterolemia upon high-fructose diet. Short-term high-fructose intake increased plasma PCSK9 levels, independent on cholesterol synthesis, suggesting a regulation independent of SREBP-2. Upon this diet, PCSK9 is associated with insulin resistance, hepatic steatosis and plasma triglycerides.
Appendix
Available only for authorised users
Literature
1.
go back to reference Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003, 100 (3): 928-933. 10.1073/pnas.0335507100.CrossRef Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003, 100 (3): 928-933. 10.1073/pnas.0335507100.CrossRef
2.
go back to reference Costet P, Krempf M, Cariou B: PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci. 2008, 33 (9): 426-434. 10.1016/j.tibs.2008.06.005.CrossRef Costet P, Krempf M, Cariou B: PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci. 2008, 33 (9): 426-434. 10.1016/j.tibs.2008.06.005.CrossRef
3.
go back to reference Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007, 32 (2): 71-77. 10.1016/j.tibs.2006.12.008.CrossRef Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007, 32 (2): 71-77. 10.1016/j.tibs.2006.12.008.CrossRef
4.
go back to reference Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34 (2): 154-156. 10.1038/ng1161.CrossRef Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34 (2): 154-156. 10.1038/ng1161.CrossRef
5.
go back to reference Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006, 354 (12): 1264-1272. 10.1056/NEJMoa054013.CrossRef Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006, 354 (12): 1264-1272. 10.1056/NEJMoa054013.CrossRef
6.
go back to reference Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012, 380 (9858): 2007-2017. 10.1016/S0140-6736(12)61770-X.CrossRef Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012, 380 (9858): 2007-2017. 10.1016/S0140-6736(12)61770-X.CrossRef
7.
go back to reference Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R: Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012, 380 (9836): 29-36. 10.1016/S0140-6736(12)60771-5.CrossRef Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R: Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012, 380 (9836): 29-36. 10.1016/S0140-6736(12)60771-5.CrossRef
8.
go back to reference Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007, 53 (10): 1814-1819. 10.1373/clinchem.2007.091280.CrossRef Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007, 53 (10): 1814-1819. 10.1373/clinchem.2007.091280.CrossRef
9.
go back to reference Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009, 55 (9): 1637-1645. 10.1373/clinchem.2009.126987.CrossRef Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009, 55 (9): 1637-1645. 10.1373/clinchem.2009.126987.CrossRef
10.
go back to reference Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J: A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010, 51 (1): 140-149. 10.1194/jlr.M900273-JLR200.CrossRef Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J: A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010, 51 (1): 140-149. 10.1194/jlr.M900273-JLR200.CrossRef
11.
go back to reference Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH: Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009, 94 (7): 2537-2543. 10.1210/jc.2009-0141.CrossRef Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH: Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009, 94 (7): 2537-2543. 10.1210/jc.2009-0141.CrossRef
12.
go back to reference Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL: Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003, 44 (11): 2109-2119. 10.1194/jlr.M300203-JLR200.CrossRef Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL: Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003, 44 (11): 2109-2119. 10.1194/jlr.M300203-JLR200.CrossRef
13.
go back to reference Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004, 24 (8): 1454-1459. 10.1161/01.ATV.0000134621.14315.43.CrossRef Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004, 24 (8): 1454-1459. 10.1161/01.ATV.0000134621.14315.43.CrossRef
14.
go back to reference Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J Biol Chem. 2006, 281 (10): 6211-6218. 10.1074/jbc.M508582200.CrossRef Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J Biol Chem. 2006, 281 (10): 6211-6218. 10.1074/jbc.M508582200.CrossRef
15.
go back to reference Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB: Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012, 15 (6): 873-884. 10.1016/j.cmet.2012.05.002.CrossRef Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB: Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012, 15 (6): 873-884. 10.1016/j.cmet.2012.05.002.CrossRef
16.
go back to reference Persson L, Galman C, Angelin B, Rudling M: Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology. 2009, 150 (3): 1140-1146.CrossRef Persson L, Galman C, Angelin B, Rudling M: Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology. 2009, 150 (3): 1140-1146.CrossRef
17.
go back to reference Browning JD, Horton JD: Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res. 2010, 51 (11): 3359-3363. 10.1194/jlr.P009860.CrossRef Browning JD, Horton JD: Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res. 2010, 51 (11): 3359-3363. 10.1194/jlr.P009860.CrossRef
18.
go back to reference Persson L, Cao G, Stahle L, Sjoberg B, Troutt JS, Konrad RJ, Galman C, Wallen H, Eriksson M, Hafstrom I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M: Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010, 30 (12): 2666-2672. 10.1161/ATVBAHA.110.214130.CrossRef Persson L, Cao G, Stahle L, Sjoberg B, Troutt JS, Konrad RJ, Galman C, Wallen H, Eriksson M, Hafstrom I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M: Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010, 30 (12): 2666-2672. 10.1161/ATVBAHA.110.214130.CrossRef
19.
go back to reference Richard C, Couture P, Desroches S, Benjannet S, Seidah NG, Lichtenstein AH, Lamarche B: Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br J Nutr. 2011, 26: 1-7. Richard C, Couture P, Desroches S, Benjannet S, Seidah NG, Lichtenstein AH, Lamarche B: Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br J Nutr. 2011, 26: 1-7.
20.
go back to reference Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlstrom H, Riserus U: Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012, 95 (5): 1003-1012. 10.3945/ajcn.111.030114.CrossRef Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlstrom H, Riserus U: Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012, 95 (5): 1003-1012. 10.3945/ajcn.111.030114.CrossRef
21.
go back to reference Guerci B, Hadjadj S, Quilliot D, Ziegler O, Drouin P: No acute response of leptin to an oral fat load in obese patients and during circadian rhythm in healthy controls. Eur J Endocrinol. 2000, 143 (5): 649-655. 10.1530/eje.0.1430649.CrossRef Guerci B, Hadjadj S, Quilliot D, Ziegler O, Drouin P: No acute response of leptin to an oral fat load in obese patients and during circadian rhythm in healthy controls. Eur J Endocrinol. 2000, 143 (5): 649-655. 10.1530/eje.0.1430649.CrossRef
22.
go back to reference Cariou B, Ouguerram K, Zair Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le MC, Gayet C, Belabbas K, Dufernez F, Chetiveaux M, Tarugi P, Krempf M, Benlian P, Costet P: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009, 29 (12): 2191-2197. 10.1161/ATVBAHA.109.194191.CrossRef Cariou B, Ouguerram K, Zair Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le MC, Gayet C, Belabbas K, Dufernez F, Chetiveaux M, Tarugi P, Krempf M, Benlian P, Costet P: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009, 29 (12): 2191-2197. 10.1161/ATVBAHA.109.194191.CrossRef
23.
go back to reference Bortolotti M, Kreis R, Debard C, Cariou B, Faeh D, Chetiveaux M, Ith M, Vermathen P, Stefanoni N, Le KA, Schneiter P, Krempf M, Vidal H, Boesch C, Tappy L: High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr. 2009, 90 (4): 1002-1010. 10.3945/ajcn.2008.27296.CrossRef Bortolotti M, Kreis R, Debard C, Cariou B, Faeh D, Chetiveaux M, Ith M, Vermathen P, Stefanoni N, Le KA, Schneiter P, Krempf M, Vidal H, Boesch C, Tappy L: High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr. 2009, 90 (4): 1002-1010. 10.3945/ajcn.2008.27296.CrossRef
24.
go back to reference Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L: Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009, 89 (6): 1760-1765. 10.3945/ajcn.2008.27336.CrossRef Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L: Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009, 89 (6): 1760-1765. 10.3945/ajcn.2008.27336.CrossRef
25.
go back to reference Theytaz F, Noguchi Y, Egli L, Campos V, Buehler T, Hodson L, Patterson BW, Nishikata N, Kreis R, Mittendorfer B, Fielding B, Boesch C, Tappy L: Effects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans. Am J Clin Nutr. 2012, 96 (5): 1008-1016. 10.3945/ajcn.112.035139.CrossRef Theytaz F, Noguchi Y, Egli L, Campos V, Buehler T, Hodson L, Patterson BW, Nishikata N, Kreis R, Mittendorfer B, Fielding B, Boesch C, Tappy L: Effects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans. Am J Clin Nutr. 2012, 96 (5): 1008-1016. 10.3945/ajcn.112.035139.CrossRef
26.
go back to reference Lindenthal B, Aldaghlas TA, Holleran AL, Sudhop T, Berthold HK, von BK, Kelleher JK: Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells. Am J Physiol Endocrinol Metab. 2002, 282 (6): E1222-E1230.CrossRef Lindenthal B, Aldaghlas TA, Holleran AL, Sudhop T, Berthold HK, von BK, Kelleher JK: Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells. Am J Physiol Endocrinol Metab. 2002, 282 (6): E1222-E1230.CrossRef
27.
go back to reference DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237 (3): E214-E223. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237 (3): E214-E223.
28.
go back to reference Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009, 29 (5): 684-690. 10.1161/ATVBAHA.108.181586.CrossRef Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009, 29 (5): 684-690. 10.1161/ATVBAHA.108.181586.CrossRef
29.
go back to reference Perseghin G, Ghosh S, Gerow K, Shulman GI: Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997, 46 (6): 1001-1009. 10.2337/diabetes.46.6.1001.CrossRef Perseghin G, Ghosh S, Gerow K, Shulman GI: Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997, 46 (6): 1001-1009. 10.2337/diabetes.46.6.1001.CrossRef
30.
go back to reference Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004, 350 (7): 664-671. 10.1056/NEJMoa031314.CrossRef Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004, 350 (7): 664-671. 10.1056/NEJMoa031314.CrossRef
31.
go back to reference Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990, 113 (12): 909-915.CrossRef Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990, 113 (12): 909-915.CrossRef
32.
go back to reference Borai A, Livingstone C, Kaddam I, Ferns G: Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011, 11: 158-10.1186/1471-2288-11-158.CrossRef Borai A, Livingstone C, Kaddam I, Ferns G: Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011, 11: 158-10.1186/1471-2288-11-158.CrossRef
33.
go back to reference Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004, 24 (8): 1448-1453. 10.1161/01.ATV.0000133684.77013.88.CrossRef Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004, 24 (8): 1448-1453. 10.1161/01.ATV.0000133684.77013.88.CrossRef
34.
go back to reference Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P: Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology. 2006, 147 (10): 4985-4995. 10.1210/en.2006-0098.CrossRef Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P: Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology. 2006, 147 (10): 4985-4995. 10.1210/en.2006-0098.CrossRef
35.
go back to reference Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD: The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000, 105 (4): 521-532. 10.1172/JCI8623.CrossRef Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD: The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000, 105 (4): 521-532. 10.1172/JCI8623.CrossRef
36.
go back to reference Tappy L, Le KA: Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010, 90 (1): 23-46. 10.1152/physrev.00019.2009.CrossRef Tappy L, Le KA: Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010, 90 (1): 23-46. 10.1152/physrev.00019.2009.CrossRef
37.
go back to reference Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J: Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2009, 50 (8): 1581-1588. 10.1194/jlr.M800542-JLR200.CrossRef Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J: Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2009, 50 (8): 1581-1588. 10.1194/jlr.M800542-JLR200.CrossRef
38.
go back to reference Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW: Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol regulatory element-binding protein-2. J Lipid Res. 2007, 49 (21): 399-409.CrossRef Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW: Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol regulatory element-binding protein-2. J Lipid Res. 2007, 49 (21): 399-409.CrossRef
39.
go back to reference Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004, 86 (11): 839-848. 10.1016/j.biochi.2004.09.018.CrossRef Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004, 86 (11): 839-848. 10.1016/j.biochi.2004.09.018.CrossRef
40.
go back to reference Kempen HJ, Glatz JF, Gevers Leuven JA, DV v, Katan MB: Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988, 29 (9): 1149-1155. Kempen HJ, Glatz JF, Gevers Leuven JA, DV v, Katan MB: Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988, 29 (9): 1149-1155.
41.
go back to reference Nissinen MJ, Gylling H, Miettinen TA: Responses of surrogate markers of cholesterol absorption and synthesis to changes in cholesterol metabolism during various amounts of fat and cholesterol feeding among healthy men. Br J Nutr. 2008, 99 (2): 370-378.CrossRef Nissinen MJ, Gylling H, Miettinen TA: Responses of surrogate markers of cholesterol absorption and synthesis to changes in cholesterol metabolism during various amounts of fat and cholesterol feeding among healthy men. Br J Nutr. 2008, 99 (2): 370-378.CrossRef
42.
go back to reference Kourimate S, Le MC, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, Nguyen P, Krempf M, Cariou B, Costet P: Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008, 283 (15): 9666-9673. 10.1074/jbc.M705831200.CrossRef Kourimate S, Le MC, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, Nguyen P, Krempf M, Cariou B, Costet P: Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008, 283 (15): 9666-9673. 10.1074/jbc.M705831200.CrossRef
43.
go back to reference Wu M, Dong B, Cao A, Li H, Liu J: Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis. 2012, 224 (2): 401-410. 10.1016/j.atherosclerosis.2012.08.012.CrossRef Wu M, Dong B, Cao A, Li H, Liu J: Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis. 2012, 224 (2): 401-410. 10.1016/j.atherosclerosis.2012.08.012.CrossRef
44.
go back to reference Cabezas MC, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW: Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med. 1998, 244 (4): 299-307. 10.1046/j.1365-2796.1998.00367.x.CrossRef Cabezas MC, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW: Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med. 1998, 244 (4): 299-307. 10.1046/j.1365-2796.1998.00367.x.CrossRef
45.
go back to reference Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagne C, Couture P: Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis. 2004, 172 (2): 367-373. 10.1016/j.atherosclerosis.2003.11.011.CrossRef Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagne C, Couture P: Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis. 2004, 172 (2): 367-373. 10.1016/j.atherosclerosis.2003.11.011.CrossRef
46.
go back to reference Niesen M, Bedi M, Lopez D: Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys. 2008, 470 (2): 111-115. 10.1016/j.abb.2007.11.009.CrossRef Niesen M, Bedi M, Lopez D: Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys. 2008, 470 (2): 111-115. 10.1016/j.abb.2007.11.009.CrossRef
47.
go back to reference Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M, Scott FW: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2009, 584 (4): 701-706.CrossRef Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M, Scott FW: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2009, 584 (4): 701-706.CrossRef
48.
go back to reference Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, Pattou F, Costet P, Cariou B: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009, 390 (4): 1288-1293. 10.1016/j.bbrc.2009.10.138.CrossRef Langhi C, Le May C, Gmyr V, Vandewalle B, Kerr-Conte J, Krempf M, Pattou F, Costet P, Cariou B: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009, 390 (4): 1288-1293. 10.1016/j.bbrc.2009.10.138.CrossRef
49.
go back to reference Tappy L, Le KA, Tran C, Paquot N: Fructose and metabolic diseases: new findings, new questions. Nutrition. 2010, 26 (11–12): 1044-1049.CrossRef Tappy L, Le KA, Tran C, Paquot N: Fructose and metabolic diseases: new findings, new questions. Nutrition. 2010, 26 (11–12): 1044-1049.CrossRef
50.
go back to reference Cariou B, Le Bras M, Langhi C, Le MC, Guyomarc'h-Delasalle B, Krempf M, Costet P: Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis. 2010, 211 (2): 700-702. 10.1016/j.atherosclerosis.2010.04.015.CrossRef Cariou B, Le Bras M, Langhi C, Le MC, Guyomarc'h-Delasalle B, Krempf M, Costet P: Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis. 2010, 211 (2): 700-702. 10.1016/j.atherosclerosis.2010.04.015.CrossRef
Metadata
Title
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
Authors
Bertrand Cariou
Cédric Langhi
Maëlle Le Bras
Murielle Bortolotti
Kim-Anne Lê
Fanny Theytaz
Cédric Le May
Béatrice Guyomarc’h-Delasalle
Yassine Zaïr
Roland Kreis
Chris Boesch
Michel Krempf
Luc Tappy
Philippe Costet
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2013
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/1743-7075-10-4

Other articles of this Issue 1/2013

Nutrition & Metabolism 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.